Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is almost never curable with the current standard treatment consisting of surgical resection, irradiation and temozolomide. The prognosis remains poor despite undisputable advances in the understanding of this tumor’s molecular biology and pathophysiology, which unfortunately has so far failed to translate into a meaningful clinical benefit. Dysregulation and a resulting prominent pathophysiological role of the epidermal growth factor receptor (EGFR) have been identified in several different malignant tumor entities, GBM among them. The EGFR is overexpressed in about 40% of GBM cases, and half of these coexpress a mutant, constitutively activated subtype, EGFRvIII. Unfortunately, recent trials studying with therapeutic approaches targeted against the EGFR and EGFRvIII have failed to meet expectations, with only a minority of patients responding despite evidence of good in vitro and rodent model activity. Having potentially high relevance within this context, epithelial to mesenchymal transition (EMT) is a phenomenon associated with early stages of carcinogenesis, cancer invasion and recurrence. During EMT, epithelial cells lose many of their epithelial characteristics, prominently E-cadherin expression, and acquire properties that are typical for mesenchymal cells such as the expression of vimentin. Epithelial to mesenchymal transition has been specifically demonstrated in GBM. In this review, we summarize the evidence that EMT may precipitate GBM resistance to EGFR-targeted therapy, and may thus be among the principal factors contributing to the clinical failure of targeted therapy against EGFR and EGFRvIII.
References
[1]
Suda, K.; Tomizawa, K.; Fujii, M; Murakami, H.; Osada, H.; Maehara, Y.; Yatabe, Y.; Sekido, Y.; Mitsudami, T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 2011, 6, 1152–1161, doi:10.1097/JTO.0b013e318216ee52.
[2]
Chung, J.H.; Rho, J.K.; Xu, X.; Lee, J.S.; Yoon, H.I.; Lee, C.T.; Choi, Y.J.; Kim, H.R.; Kim, C.H.; Lee, J.C. Clinical and molecular evidence of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2011, 2, 176–182.
[3]
Thomson, S.; Petti, F.; Sujka-Kwok, I.; Epstein, D.; Haley, J.D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 2008, 8, 843–854.
[4]
Rho, J.K.; Chou, I.J.; Lee, J.K.; Ryoo, B.Y.; Na, I.I.; Yang, S.H.; Kim, C.H.; Lee, J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2008, 2, 219–226.
L？w, S.; Schmidt, U.; Unterberg, A.; Halatsch, M.-E. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med. Chem. 2009, 9, 703–715, doi:10.2174/187152009788680019. 19601750
[7]
Haddad, Y.; Woonyoung, C.; McConkey, J.D. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin. Cancer Res. 2009, 2, 532–542.
[8]
Krakstad, C.; Chekenya, M. Survival signaling and apoptosis resistance in glioblastomas: Opportunities for targeted therapeutics. Mol. Cancer 2010, 9, 135–149, doi:10.1186/1476-4598-9-135. 20515495
[9]
Deng, Q.-F.; Zhou, C.-C.; Su, C.-X. Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer. Respirology 2009, 14, 371–376, doi:10.1111/j.1440-1843.2009.01496.x. 19353773
[10]
Fuchs, B.C.; Fujii, T.; Dorfman, J.D.; Goodwin, J.M.; Zhu, A.X.; Lanuti, M.; Tanabe, K.K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 2008, 7, 2391–2399.
[11]
Wever, O.D.; Pauwels, P.; Craene, B.D.; Michèle, S.; Emami, S.; Redeuilh, G.; Gespach, C.; Berx, G. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem. Cell Biol. 2008, 130, 481–494, doi:10.1007/s00418-008-0464-1. 18648847
[12]
Larue, L.; Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3 kinase/AKT pathways. Oncogene 2005, 24, 7443–7454, doi:10.1038/sj.onc.1209091. 16288291
[13]
Xu, J.; Lamouille, S.; Derynck, R. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009, 19, 156–172, doi:10.1038/cr.2009.5. 19153598
[14]
Mikheeva, S.A.; Mikheev, A.M.; Petit, A.; Beyer, R.; Oxford, R.G.; Khorasani, L.; Maxwell, J.P.; Glackin, C.A.; Wakimoto, H.; González-Herrero, I.; et al. Twist 1 promotes invasion through mesenchymal change in human glioblastoma. Mol. Cancer 2010, 9, 194–212, doi:10.1186/1476-4598-9-194. 20646316
Tektonidis, M.; Haralambos, H.; Chauviere, A.; Simon, M.; Schaller, K.; Deutsch, A. Identification of intrinsic in vitro cellular mechanisms for glioma invasion. J. Theor. Biol. 2011, 287, 131–147, doi:10.1016/j.jtbi.2011.07.012.
[17]
Qiao, B.; Johnson, N.W.; Gao, J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-β1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Oncology 2010, 37, 663–668.
[18]
Han, S.P.; Kim, J.H.; Han, M.E.; Sim, H.E.; Kim, K.S.; Yoon, S.; Baek, S.Y.; Kim, B.S.; Oh, S.O. Snai 1 is involved in the proliferation and migration of glioblastoma cells. Cell. Mol. Neurobiol. 2011, 31, 489–496, doi:10.1007/s10571-010-9643-4. 21225336
[19]
Xun, J.; Hee-Young, J.; Kveung, M.J.; Kim, J.K.; Jin, J.; Kim, S.H.; Kang, B.G.; Beck, S.; Lee, S.J.; Kim, J.K.; et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 2011, 71, 3066–3075, doi:10.1158/0008-5472.CAN-10-1495. 21363911
[20]
Katoh, M.; Katoh, M. Comparative genomics on SNAI 1, SNAI 2, and SNAI 3 orthologs. Oncol. Rep. 2005, 14, 1083–1086. 16142376
[21]
Xia, M.; Hu, M.; Wang, J.; Xu, Y.; Chen, X.; Ma, Y.; Su, L. Identification of the role of Smad interacting protein 1 (SIP 1) in glioma. J. Neurooncol. 2010, 97, 225–232, doi:10.1007/s11060-009-0015-1. 19806322
[22]
Yang, H.W.; Menon, L.G.; Black, P.M.; Carroll, R.S.; Johnson, M.D. SNAI2/SLUG promotes growth and invasion in human gliomas. BMC Cancer 2010, 10, 301, doi:10.1186/1471-2407-10-301. 20565806
[23]
Lee, M.Y.; Chou, C.Y.; Tang, M.J.; Shen, M.R. Epithelial-mesenchymal transition in cervical cancer: Correlation with tumor progression, epidermal growth factor receptor overexpression, and Snail up-regulation. Clin. Cancer Res. 2008, 15, 4743–4750.
[24]
Koppikar, P.; Lui, V.W.Y.; Man, D.; Xi, S.; Chai, R.L.; Nelson, E.; Tobey, A.B.J.; Grandis, J.R. Constitutive activation of signal tranducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition and resistance to epidermal growth factor receptor targeting. Clin. Cancer Res. 2008, 14, 7682–7690, doi:10.1158/1078-0432.CCR-08-1328. 19047094
[25]
Chi, A.S. Rapid radiographic and clinical improvement after treatment of MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J. Clin. Oncol. 2012, 30, 30–33, doi:10.1200/JCO.2011.38.4586.
[26]
Moon, Y.-W.; Weil, R.J.; Pack, S.D.; Park, W.-S.; Park, E.; Pham, T.; Karkera, J.D.; Kim, H.-K.; Vortmeyer, A.O.; Fuller, B.G.; et al. Missense mutation of the MET gene detected in human glioma. Mod. Pathol. 2000, 13, 973–977, doi:10.1038/modpathol.3880177.
